Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

2736 - Eribulin demonstrate selectively high sensitivity to recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) cells and xenograft tumors

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Cancer Biology

Tumour Site

Head and Neck Cancers

Presenters

hiroko kitahara

Citation

Annals of Oncology (2018) 29 (suppl_8): viii1-viii13. 10.1093/annonc/mdy268

Authors

H. kitahara, Y. Kobayashi, M. Hirai, S. Kawashiri, H. Nakamura

Author affiliations

  • Oral And Maxillofacial Surgery, Kanazawa University Hospital, 9208641 - Kanazawa/JP

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2736

Background

Recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) is a devastating malignancy with a poor prognosis. Eribulin (a microtubule inhibitor) reportedly renders breast cancer less aggressive, and less likely to metastasise, by triggering the mesenchymal-to-epithelial (MET) transition. Previously we reported that eribulin-induced MET was associated with re-sensitization of resistant HNSCC cell lines to cetuximab. In this study, we evaluated eribulin activity in preclinical R/M HNSCC models.

Methods

In vitro antiproliferative activities (IC50) were determined in three human HNSCC cell lines (OSC-20, OSC-19 and OLC01) treated with eribulin or other microtubule inhibitors (paclitaxel and vinblastine). The effects of eribulin were evaluated in eribulin-sensitive and -resistant HNSCC xenograft tumors.

Results

Eribulin demonstrate selectively high sensitivity to OLC01 cells (R/M HNSCC) in comparison with other cell lines. Eribulin has sub-0.1 nM growth inhibitory activities in vitro against OLC01 cells as well as marked in vivo activities at 0.1–0.5 mg/kg against OLC01 cells xenografts. Inducible TUBB3 correlates with lower sensitivity to eribulin in HNSCC cells and xenograft tumors.

Conclusions

Understanding the mechanisms involved in the overall drug response to eribulin may help in the design of therapeutic strategies that enhance drug activity and improve benefits of eribulin in R/M HNSCC patients.

Clinical trial identification

Legal entity responsible for the study

Graduate School of Medical Science, Kanazawa University.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.